FTC closes probe into Celgene's alleged REMS abuse
The US Federal Trade Commission said it has closed an investigation into Celgene over allegations that it sought to block rivals from offering generic versions of the cancer drugs Thalomid and...To view the full article, register now.
Already a subscriber? Click here to view full article